Macrolide therapy for the prevention of acute exacerbations in chronic obstructive pulmonary disease

Polskie Archiwum Medycyny Wewnetrznej

Volumn 122, Issue 1-2, 2012, Pages 54-59

  Mammen, Manoj J ^a   Sethi, Sanjay ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Antibiotic prophylaxis; Chronic obstructive pulmonary disease; Exacerbation; Macrolide

Indexed keywords

AZITHROMYCIN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLARITHROMYCIN; CORTICOSTEROID; ERYTHROMYCIN; INFLUENZA VACCINE; MACROLIDE; PNEUMOCOCCUS VACCINE;

ANTIBIOTIC SENSITIVITY; ANTIINFLAMMATORY ACTIVITY; BACTERIAL FLORA; BRONCHIOLITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; DEFENSE MECHANISM; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFECTION CONTROL; INFLUENZA VACCINATION; LOW DRUG DOSE; LUNG FUNCTION; PATIENT MONITORING; PULMONARY REHABILITATION; REVIEW; RISK REDUCTION; SMOKING CESSATION; SPUTUM EXAMINATION; TREATMENT DURATION;

EID: 84857553880     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.1134     Document Type: Review

References (31)

1. National Heart, Lung, and Blood Institute. 2009 NHLBI morbidity and mortality chartbook on cardiovascular, lung and blood diseases [Internet]. Bethesda, MD: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health. http://www.nhlbi.nih.gov/resources/ docs/cht-book.htm. Accessed July 2, 2011.
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997; 349: 1498-1504. (Pubitemid 27216360)
3. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease, Revised 2011. http://www.goldcopd.org/ uploads/users/files/GOLD2011-Summary.pdf. December 23, 2011.
4. Kanner RE, Anthonisen NR, Connett JE; Lung Health Study Research Group. Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med. 2001; 164: 358-364. (Pubitemid 32778199)
5. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002; 57: 847-852. (Pubitemid 35178607)
6. Quint JK, Baghai-Ravary R, Donaldson GC, Wedzicha JA. Relationship between depression and exacerbations in COPD. Eur Respir J. 2008; 32: 53-60.
7. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998; 157: 1418-1422.
8. Spencer S, Jones PW; GLOBE Study Group. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax. 2003; 58: 589-593. (Pubitemid 36808129)
9. Miravitlles M, Murio C, Guerrero T. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. DAFNE Study Group. Eur Respir J. 2001; 17: 928-933. (Pubitemid 32600341)
10. Adams SG, Melo J, Luther M, Anzueto A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 2000; 117: 1345-1352. (Pubitemid 30321589)
11. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005; 60: 925-931. (Pubitemid 41598207)
12. Stoller JK. Clinical practice. Acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 2002; 346: 988-994. (Pubitemid 34983250)
13. Andersson F, Borg S, Jansson SA, et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med. 2002; 96: 700-708.
14. Miravitlles M, Jardim JR, Zitto T, et al. [Pharmacoeconomic study of antibiotic therapy for exacerbations of chronic bronchitis and chronic obstructive pulmonary disease in Latin America]. Arch Bronconeumol. 2003; 39: 549-553. Spanish.
15. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977; 1: 1645-1648. (Pubitemid 8124466)
16. Tashkin DP. Preventing and managing exacerbations in COPD - critical appraisal of the role of tiotropium. Int J Chron Obstruct Pulmon Dis. 2010; 5: 41-53.
17. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007; 146: 545-555. (Pubitemid 351650535)
18. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010; 363: 1128-1138.
19. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008; 359: 2355-2365.
20. Dransfield MT, Nahm MH, Han MK, et al.; COPD Clinical Research Network. Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009; 180: 499-505.
21. Sethi S, Wrona C, Grant BJB, Murphy TF. Strain specific immune response to Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004; 169: 448-453. (Pubitemid 38187115)
22. Black P, Staykova T, Chacko E, et al. Prophylactic antibiotic therapy for chronic bronchitis. Cochrane Database Syst Rev. 2003: CD004 105.
23. Shinkai M, Foster GH, Rubin BK. Macrolide antibiotics modulate ERK phosphorylation and IL-8 and-CSF production by human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2006; 290: L75-85.
24. Shinkai M, Henke MO, Rubin BK. Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharmacol Ther. 2008; 117: 393-405.
25. Marjanović N, Bosnar M, Michielin F, et al. Macrolide antibiotics broadly and distinctively inhibit cytokine and chemokine production by COPD sputum cells in vitro. Pharmacol Res. 2011; 63: 389-397.
26. Suzuki T, Yanai M, Yamaya M, et al. Erythromycin and common cold in COPD. Chest. 2001; 120: 730-733. (Pubitemid 32885442)
27. Banerjee D, Khair OA, Honeybourne D. The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respir Med. 2005; 99: 208-215. (Pubitemid 40104276)
28. Seemungal TA, Wilkinson TM, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008; 178: 1139-1147.
29. Albert RK, Connett J, Bailey WC, et al.; COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011; 365: 689-698.
30. Peckham DG. Macrolide antibiotics and cystic fibrosis. Thorax. 2002; 57: 189-190. (Pubitemid 34214402)
31. Sethi S. Infection as a comorbidity of COPD. Eur Respir J. 2010; 35: 1209-1215.